crizanlizumab
Trade name: Adakveo
mAbapprovedOrphan Drug FDABreakthrough Therapy FDA
Approved
Nov 15, 2019
Crizanlizumab, sold under the brand name Adakveo among others, is a monoclonal antibody medication that binds to P-selectin. It is a medication used to reduce the frequency of vaso-occlusive crisis in people aged 16 years and older who have sickle cell anemia. It is given by injection into a vein. — Wikipedia
Clinical trial activity
16 trials · 9 clinical orgs · 1 marketing orgs
Phase 1
2
Phase 2
12
Phase 3
2
Phase 4
2
Earliest trial started Jul 1, 2013 (NCT01895361)
Timeline
2000s
- Jul 22, 2008
Orphan Drug Designation
Indications
Approved for
Mechanism of action
- P-selectinBLOCKER
P-selectin blocker
Binds P-selectin on the surface of the activated endothelium and platelets and blocks it's interaction with ligands on other cells, this reduces cell adhesion.
- P-selectinImmunity, passive
SELP immunity, passive
Approval history
- approvedPriority reviewBreakthroughNov 15, 2019
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral
- Availability
- Prescription Only
- Multi-specific
- No
Oral
No
Parenteral
Yes
Topical
No
First in class
Sources
- WikipediaCrizanlizumab ↗
- NCATSL7451S9126 ↗
- ChEMBLCHEMBL4297734 ↗
Also known as
- selg1
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06439082 | Phase 3 | Oct 1, 2024 | Novartis |
| NCT05909618 | Phase 2 | Jul 11, 2023 | Tel Aviv University |
| NCT05469828 | Phase 1/Phase 2 (Phase 2) | Jul 1, 2023 | Children's Hospital Los Angeles, Novartis |
| NCT05334576 | N/A | Apr 11, 2022 | Novartis, Washington University in St. Louis |
| NCT04657822 | Phase 4 | Apr 28, 2021 | Novartis |
| NCT04662931 | Phase 4 | Jan 26, 2021 | Novartis |
| NCT04611880 | Phase 2 | Dec 1, 2020 | Washington University in St. Louis |
| NCT04435184 | Phase 2 | Jun 30, 2020 | Harvard University, Johns Hopkins University, Novartis, Socar Research SA |
| NCT04053764 | Phase 2 | Oct 1, 2019 | Novartis |
| NCT04097821 | Phase 1/Phase 2 (Phase 2) | Sep 18, 2019 | Novartis |
| NCT03938454 | Phase 2 | Sep 2, 2019 | Novartis |
| NCT03814746 | Phase 3 | Jul 25, 2019 | Novartis |
| NCT03474965 | Phase 2 | Aug 30, 2018 | Novartis |
| NCT03264989 | Phase 2 | Dec 19, 2017 | Novartis |
| NCT01895361 | Phase 2 | Jul 1, 2013 | National Heart, Lung, and Blood Institute (NHLBI), Selexys Pharmaceuticals Corporation |
| NCT03720626 | N/A | — | Novartis |
Showing 16 of 16 trials
Page 1 / 1
Organizations
Research & Development (9)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Novartis | For profit | 13 | 10 | 4 | 2017 |
| Washington University in St. Louis | Academic/Hospital | 2 | 2 | 2 | 2020 |
| Children's Hospital Los Angeles | Academic/Hospital | 1 | 1 | 1 | 2023 |
| Harvard University | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Johns Hopkins University | Academic/Hospital | 1 | 1 | 1 | 2020 |
| National Heart, Lung, and Blood Institute (NHLBI) | Government | 1 | 0 | 1 | 2013 |
| Selexys Pharmaceuticals Corporation | For profit | 1 | 1 | 1 | 2013 |
| Socar Research SA | For profit | 1 | 0 | 1 | 2020 |
| Tel Aviv University | Academic/Hospital | 1 | 1 | 1 | 2023 |
9 organizations
Page 1 / 1